Sukhmani K. Padda

5.1k total citations
94 papers, 1.5k citations indexed

About

Sukhmani K. Padda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Sukhmani K. Padda has authored 94 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 58 papers in Oncology and 20 papers in Neurology. Recurrent topics in Sukhmani K. Padda's work include Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Research Studies (28 papers) and Myasthenia Gravis and Thymoma (17 papers). Sukhmani K. Padda is often cited by papers focused on Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Research Studies (28 papers) and Myasthenia Gravis and Thymoma (17 papers). Sukhmani K. Padda collaborates with scholars based in United States, India and Canada. Sukhmani K. Padda's co-authors include Heather A. Wakelee, Joel W. Neal, Millie Das, Jessica A. Hellyer, Jonathan W. Riess, Jacqueline V. Aredo, Kavitha Ramchandran, Maximilian Diehn, Joseph B. Shrager and Bryan M. Burt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Sukhmani K. Padda

85 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sukhmani K. Padda United States 21 724 640 368 317 181 94 1.5k
Fumihiko Hirai Japan 26 1.1k 1.5× 979 1.5× 439 1.2× 173 0.5× 181 1.0× 103 1.8k
Satoshi Igawa Japan 18 755 1.0× 597 0.9× 299 0.8× 164 0.5× 125 0.7× 100 1.2k
Teresa Alonso‐Gordoa Spain 19 619 0.9× 343 0.5× 366 1.0× 253 0.8× 239 1.3× 82 1.2k
Takehito Shukuya Japan 29 1.4k 2.0× 1.5k 2.4× 610 1.7× 130 0.4× 438 2.4× 130 2.5k
Y. Ichinose Japan 20 721 1.0× 922 1.4× 211 0.6× 104 0.3× 102 0.6× 78 1.3k
Rutika Mehta United States 19 556 0.8× 295 0.5× 468 1.3× 97 0.3× 331 1.8× 73 1.3k
Akira Ono Japan 29 1.7k 2.4× 1.9k 2.9× 388 1.1× 197 0.6× 393 2.2× 183 2.9k
Ana Custodio Spain 21 705 1.0× 306 0.5× 301 0.8× 246 0.8× 175 1.0× 75 1.2k
Fei Yuan China 23 473 0.7× 447 0.7× 384 1.0× 103 0.3× 323 1.8× 69 1.5k
Aradhana Kaushal United States 20 203 0.3× 577 0.9× 341 0.9× 126 0.4× 176 1.0× 38 1.3k

Countries citing papers authored by Sukhmani K. Padda

Since Specialization
Citations

This map shows the geographic impact of Sukhmani K. Padda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sukhmani K. Padda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sukhmani K. Padda more than expected).

Fields of papers citing papers by Sukhmani K. Padda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sukhmani K. Padda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sukhmani K. Padda. The network helps show where Sukhmani K. Padda may publish in the future.

Co-authorship network of co-authors of Sukhmani K. Padda

This figure shows the co-authorship network connecting the top 25 collaborators of Sukhmani K. Padda. A scholar is included among the top collaborators of Sukhmani K. Padda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sukhmani K. Padda. Sukhmani K. Padda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Aredo, Jacqueline V., Heather A. Wakelee, Kavitha Ramchandran, et al.. (2024). Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC. JTO Clinical and Research Reports. 5(12). 100741–100741. 1 indexed citations
3.
4.
5.
Padda, Sukhmani K., Mary W. Redman, David E. Gerber, et al.. (2023). ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). TPS9143–TPS9143. 2 indexed citations
6.
Kim, Sungjin, Nina N. Sanford, Ann C. Raldow, et al.. (2023). Association of Parental Status and Gender With Burden of Multidisciplinary Tumor Boards Among Oncology Physicians. JAMA Network Open. 6(10). e2340663–e2340663. 4 indexed citations
7.
Hellyer, Jessica A., et al.. (2022). Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. JTO Clinical and Research Reports. 3(5). 100323–100323. 5 indexed citations
8.
Piper‐Vallillo, Andrew J., Rebecca M. Gardner, Kristen Cunanan, et al.. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer. 23(3). e210–e221. 14 indexed citations
9.
Aredo, Jacqueline V., Heather A. Wakelee, Joel W. Neal, & Sukhmani K. Padda. (2021). Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications. 30. 100497–100497. 7 indexed citations
10.
Hellyer, Jessica A., Rebecca M. Gardner, Kristen Cunanan, et al.. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer. 23(3). 264–272. 17 indexed citations
11.
Hellyer, Jessica A., Sukhmani K. Padda, Maximilian Diehn, & Heather A. Wakelee. (2020). Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. Journal of Thoracic Oncology. 16(3). 395–403. 39 indexed citations
12.
Hellyer, Jessica A., Madhu M. Ouseph, Sukhmani K. Padda, & Heather A. Wakelee. (2020). Everolimus in the treatment of metastatic thymic epithelial tumors. Lung Cancer. 149. 97–102. 12 indexed citations
13.
Assi, Hussein & Sukhmani K. Padda. (2020). Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung. Cancer Treatment and Research Communications. 23. 100167–100167. 5 indexed citations
14.
Jeong, Youngtae, Jessica A. Hellyer, Henning Stehr, et al.. (2019). Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(1). 274–281. 80 indexed citations
15.
Hellyer, Jessica A., Matthew A. Gubens, Kristen Cunanan, et al.. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer. 137. 71–75. 11 indexed citations
16.
17.
Bergsland, Emily K., Thomas A. Hope, Pamela L. Kunz, et al.. (2018). P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus. Journal of Thoracic Oncology. 13(10). S575–S575. 1 indexed citations
18.
Burt, Bryan M., Xiaopan Yao, Joseph B. Shrager, et al.. (2016). Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. Journal of Thoracic Oncology. 12(1). 129–136. 71 indexed citations
19.
Wakelee, Heather A., Sukhmani K. Padda, Matthew Burns, et al.. (2015). Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies. Journal of Thoracic Disease. 7(3). 101. 1 indexed citations
20.
Wakelee, Heather A., Sukhmani K. Padda, Matthew Burns, et al.. (2015). Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).. Journal of Clinical Oncology. 33(15_suppl). 7580–7580. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fumihiko Hirai Breakdown of academic impact, for papers by Satoshi Igawa Breakdown of academic impact, for papers by Teresa Alonso‐Gordoa Breakdown of academic impact, for papers by Takehito Shukuya Breakdown of academic impact, for papers by Y. Ichinose Breakdown of academic impact, for papers by Rutika Mehta Breakdown of academic impact, for papers by Akira Ono Breakdown of academic impact, for papers by Ana Custodio Breakdown of academic impact, for papers by Fei Yuan Breakdown of academic impact, for papers by Aradhana Kaushal
Rankless by CCL
2026